<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02906059</url>
  </required_header>
  <id_info>
    <org_study_id>14-01168</org_study_id>
    <nct_id>NCT02906059</nct_id>
  </id_info>
  <brief_title>Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase Ib Study Combining Irinotecan With AZD1775, a Selective Wee 1 Inhibitor, in RAS (KRAS or NRAS) or BRAF Mutated Metastatic Colorectal Cancer Patients Who Have Progressed on First Line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether combination therapy of irinotecan with&#xD;
      AZD1775 is safe and effective in treating mutated metastatic colorectal cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">March 12, 2020</completion_date>
  <primary_completion_date type="Actual">March 12, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants dose limiting toxicities with treatment-related adverse events as assessed by common terminology criteria for adverse events (CTCAE), version 4.</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor assessment by imaging techniques using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1</measure>
    <time_frame>From baseline to every 8 weeks up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>AZD1775 &amp; Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group AZD1775 (study drug); Irinotecan (chemotherapy)&#xD;
1) 125 mg two times a day (BID) for 3 days every 2 weeks; 180mg/m2 every 2 weeks&#xD;
2A) 150 mg BID for 3 days every 2 weeks; 180mg/m2 every 2 weeks&#xD;
2B) 125 mg BID for 5 days every 2 weeks; 180mg/m2 every 2 weeks&#xD;
3) 150 mg BID for 5 days every 2 weeks ; 180mg/m2 every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1775</intervention_name>
    <arm_group_label>AZD1775 &amp; Irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>AZD1775 &amp; Irinotecan</arm_group_label>
    <other_name>Camptosar, Campto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide signed and dated informed consent prior to any study specific procedures&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Histological or cytological confirmation of Colorectal Cancer (CRC) with available&#xD;
             tissue, currently stage IV&#xD;
&#xD;
          -  Failure of first-line anti-cancer therapy with an oxaliplatin and bevacizumab based&#xD;
             regimen (either radiological documentation of disease progression or due to toxicity)&#xD;
             or subsequent relapse of disease following first-line therapy. Patients relapsing&#xD;
             within 12 months of completing adjuvant FOLFOX will also be considered eligible.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 1&#xD;
&#xD;
          -  At least one lesion, not previously irradiated, that can be accurately measured as ≥&#xD;
             10 mm in the longest diameter (LD) with spiral computed tomography (CT) scan or as ≥&#xD;
             20 mm with conventional techniques (conventional CT, MRI) and which is suitable for&#xD;
             accurate repeated measurements&#xD;
&#xD;
          -  Tumor sample confirmed as KRAS or NRAS [codons 12 and 13 (exon 2), 59 and 61 (exon 3),&#xD;
             and 117 and 146 (exon 4)] or BRAF [codon 600 (exon 15)] mutation positive.&#xD;
&#xD;
          -  Patients must be able to swallow AZD1775 capsules&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment within 14 days prior to first study treatment with conventional therapy or&#xD;
             treatment within 28 days prior to first study treatment with an investigational drug&#xD;
&#xD;
          -  Received more than 1 line of systemic treatment for advanced/metastatic CRC and/or a&#xD;
             patient whose first line therapy did not contain oxaliplatin and bevacizumab&#xD;
&#xD;
          -  Prior treatment with a Wee1 inhibitor or any irinotecan containing regimen&#xD;
&#xD;
          -  Any unresolved toxicity ≥ CTCAE Grade 2 from previous anti-cancer therapy, except for&#xD;
             alopecia and neurotoxicity.&#xD;
&#xD;
          -  The last radiation therapy within 4 weeks prior to starting study treatment, or&#xD;
             limited field of radiation for palliation within 2 weeks of the first dose of study&#xD;
             treatment&#xD;
&#xD;
          -  Recent major surgery within 4 weeks prior to entry into the study (excluding the&#xD;
             placement of vascular access) which would prevent administration of study treatment&#xD;
&#xD;
          -  History of hypersensitivity to AZD1775, irinotecan, or any excipients of these agents&#xD;
&#xD;
          -  Brain metastases or spinal cord compression unless asymptomatic, treated and stable&#xD;
             off steroids and anti-convulsants for at least 3 months&#xD;
&#xD;
          -  Laboratory values as listed below (from laboratory results during screening):&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) &lt;1.5 x 10^9/L (1500 per mm3)&#xD;
&#xD;
               -  Platelets &lt; 100 x 109/L (100,000 per mm3)&#xD;
&#xD;
               -  Hemoglobin &lt;9.0 g/dL&#xD;
&#xD;
               -  Serum bilirubin &gt;Upper Limit of Normal (ULN)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT):&#xD;
&#xD;
                    -  &gt; 2.5 x ULN&#xD;
&#xD;
                    -  &gt; 5 x ULN, if liver metastasis present&#xD;
&#xD;
               -  Creatinine clearance &lt; 50 cc/min measured or calculated by Cockcroft Gault&#xD;
                  equation - Cardiac conditions as follows:&#xD;
&#xD;
               -  Uncontrolled hypertension (BP ≥ 170/100 despite optimal therapy)&#xD;
&#xD;
               -  Heart failure New York Heart Association (NYHA) Class II or above&#xD;
&#xD;
               -  Prior or current cardiomyopathy&#xD;
&#xD;
               -  If NYHA Class I heart failure, Left Ventricular Ejection Fraction (LVEF) by Multi&#xD;
                  Gated Acquisition Scan (MUGA) or Echocardiogram (ECHO) is less than 50%&#xD;
&#xD;
               -  Unstable ischemic heart disease (myocardial infarction within 6 months prior to&#xD;
                  starting treatment, or angina requiring use of nitrates more than once weekly)&#xD;
&#xD;
               -  Mean resting corrected QT (QTc) interval using the Fridericia formula (QTcF) &gt;&#xD;
                  450 msec/male and &gt; 470 msec/female (as calculated per institutional standards)&#xD;
                  obtained from 3 electrocardiograms (ECGs) 2-5 minutes apart at study entry, or&#xD;
                  congenital long QT syndrome&#xD;
&#xD;
               -  Patients with significant ventricular or supraventricular arrhythmias and&#xD;
                  patients with cardiac conduction abnormalities that are not controlled (e.g. with&#xD;
                  a pacemaker or medication).&#xD;
&#xD;
          -  Any evidence of severe or uncontrolled systemic disease, active infection, active&#xD;
             bleeding diatheses or renal transplant, including any patient known to have hepatitis&#xD;
             B, hepatitis C or human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory&#xD;
             bowel disease), or significant bowel resection that would preclude adequate ingestion&#xD;
             and absorption of an oral agent&#xD;
&#xD;
          -  Clinical evidence of bowel obstruction at the time of study entry&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding, or male or female patients of&#xD;
             reproductive potential who are not employing an effective method of birth control&#xD;
&#xD;
          -  History of another primary malignancy within 5 years prior to starting study&#xD;
             treatment, except for adequately treated basal or squamous cell carcinoma of the skin&#xD;
             or cancer of the cervix in situ. Patients with an early stage cancer, now off therapy&#xD;
             for at least 3 years may be enrolled with permission of the PI if that disease is&#xD;
             unlikely to interfere with the primary endpoints of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deirdre Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Perlmutter Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RAS</keyword>
  <keyword>KRAS</keyword>
  <keyword>NRAS</keyword>
  <keyword>BRAF</keyword>
  <keyword>Mutated</keyword>
  <keyword>Wee1 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Adavosertib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

